Table 3.
Bivariable Associations With Clearancea of Anal Non-16 High-Risk Human Papillomavirus (HPV), HPV-16, and All High-Risk HPV
| Variable | Hazard Ratio (95% CI) |
||
|---|---|---|---|
| Clearance of Type-Specific Non-16 HR-HPVb (n = 227)c | Clearance of HPV-16 (n = 34)d | Clearance of All HR-HPVa (n = 75)e | |
| Age, per y | 1.02 (.97–1.06) | 0.99 (.90–1.08) | 0.96 (.89–1.03)a |
| Concurrent cervical HPV (with same HR type) at visit, yes vs no | 0.08 (.04–.16)** | 0.26 (.09–.75)** | 0.12 (.02–.89)** |
| Concurrent cervical HPV (with otherf HR type) at visit, yes vs no | 0.94 (.63–1.41) | 1.63 (.32–8.30) | 0.09 (.03–.3)*** |
| Previous cervical HPV (with same type) at visit, yes vs no | 0.82 (.50–1.35) | 0.98 (.38–2.54) | 0.70 (.48–1.01)* |
| Total lifetime sex partners, per partner | 1.0 (.98–1.02) | 0.95 (.90–1.01)* | 0.96 (.94–.99)** |
| Recent new sex partnerg, per partner | 1.09 (.96–1.25) | 1.34 (1.04–1.73)** | 0.96 (.80–1.15) |
| Ever had anal sex, yes vs no | 0.96 (.56–1.65) | 0.49 (.21–1.15)* | 0.44 (.24–.80)** |
| Recent anal sexg, yes vs no | 1.37 (.89–2.12) | 0.46 (.41–1.51) | 0.12 (.15–1.17)* |
| Recent sexual anal touchingg, yes vs no | 1.24 (.69–2.23) | 0.31 (.09–1.07)* | 0.56 (.25–1.27) |
| Current cigarette use, yes vs no | 1.52 (.82–2.82) | 1.06 (.29–3.85) | 1.02 (.47–2.21) |
| Weekly alcohol useg, yes vs no | 1.36 (.89–2.09) | 0.32 (.15–.70)** | 0.96 (.55–1.69) |
| Condom use during vaginal intercourseg, any use vs none | 0.85 (.57–1.28) | 3.69 (1.51–8.99)** | 1.69 (.95–2.99)* |
| Nonmonogamousg, yes vs no | 1.14 (.68–1.92) | 1.19 (.41–3.42) | 1.15 (.6–2.2) |
| No anal condom useg, vs no anal sex | 0.96 (.57–1.62) | 0.25 (.06–1.03)* | 0.27 (.06–1.1)* |
| Condom use during anal sexg, any vs no anal sex | 1.72 (.53–5.56) | NE | 0.82 (.11–6.1) |
| Months on oral contraceptivesg, per 6 mo | 1.01 (1.98–1.04) | 0.93 (.86–.99)** | 0.98 (.93–1.02) |
Abbreviations: CI, confidence interval; HPV, human papillomavirus; HR, high risk; NE, not able to estimate because too few cases.
a Clearance defined as time to 2 consecutive visits negative for all HR-HPV types.
b Includes HPV types 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73, and 82.
c Number of anal non-16 HR-HPV events qualifying for analysis.
d Number of events with anal HPV-16.
e Number of events with anal HR-HPV.
f In the case of multiple types, “other” was defined only if same type was not found.
g Reported since last visit.
*P < .1; **P < .05; ***P < .001.